Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Stock analysts at Wedbush issued their FY2029 earnings per share estimates for Alto Neuroscience in a research report issued on Thursday, March 20th. Wedbush analyst L. Chico anticipates that the company will post earnings per share of ($2.88) for the year. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.54) per share.
Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.09.
Separately, William Blair reissued an "outperform" rating on shares of Alto Neuroscience in a report on Friday. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Alto Neuroscience currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.75.
Read Our Latest Research Report on ANRO
Shares of NYSE ANRO opened at $2.71 on Monday. The business has a fifty day moving average of $3.63 and a two-hundred day moving average of $6.05. Alto Neuroscience has a 52-week low of $2.58 and a 52-week high of $18.35. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09.
Hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets increased its stake in shares of Alto Neuroscience by 619.2% in the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company's stock valued at $49,000 after buying an additional 3,715 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Alto Neuroscience during the 3rd quarter valued at about $124,000. Wells Fargo & Company MN lifted its holdings in shares of Alto Neuroscience by 40.0% during the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock valued at $46,000 after purchasing an additional 3,139 shares in the last quarter. MetLife Investment Management LLC bought a new position in shares of Alto Neuroscience during the 3rd quarter valued at about $146,000. Finally, Deutsche Bank AG lifted its holdings in shares of Alto Neuroscience by 31.3% during the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company's stock valued at $64,000 after purchasing an additional 3,629 shares in the last quarter.
Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Alto Neuroscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alto Neuroscience wasn't on the list.
While Alto Neuroscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.